Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RMTI, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Citrate FDA approved Mar 2020 · Triferic Avnu (discontinued) |
Iron-Refractory Iron-Deficiency Anemia | Phase 2 · NCT02905981 | Terminated |
| Triferic AVNU | End Stage Renal Disease | Phase 4 · NCT04689932 | Completed |
| SFP | End Stage Renal Disease | Phase 3 · NCT01503021 | Completed |
| Soluble ferric pyrophosphate | Renal Failure Chronic Requiring Hemodialysis | Phase 3 · NCT01320202 | Completed |
| Triferic | End Stage Renal Disease | Phase 3 · NCT04239391 | Unknown |
| Erythrocyte Stimulating Agent (ESA) | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
| Fer-In-Sol | Iron-Refractory Iron-Deficiency Anemia | Phase 2 · NCT02905981 | Terminated |
| Heparin | End Stage Renal Disease | Phase 1/2 · NCT04042324 | Completed |
| Iron | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
| Soluble Ferric Pyrophosphate in liquid b | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RMTI holds $24.8M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RMTI files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RMTI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →